MEDP — Medpace Holdings, Inc.
MEDP dilution and offerings
- Float: 22.5M shares
$648.14-0.59%
Last close: · regular session
Last 60 sessions
Float: 22.5M shares. Latest SEC filing: 144 on Oct 29, 2026. MEDP closed at $648.14 (-0.59%) on Nov 2, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for MEDP in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Medical - Diagnostics & Research
- Country: US
- Exchange: NASDAQ Global Select
- Employees: 5,900
- Website: https://www.medpace.com
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Latest SEC filings for MEDP
Latest MEDP news
- CON vs. MEDP: Which Stock Is the Better Value Option? Read article
- Medpace (MEDP) is a Great Momentum Stock: Should You Buy? Read article
- Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes" Read article
- All You Need to Know About Medpace (MEDP) Rating Upgrade to Buy Read article
- Medpace: 3 Key Takeaways for Long-Term Investors Read article
- Medpace forecasts 2026 EPS of $17.97-$18.32 as $1B buyback authorization replaces prior program Read article
- Medpace raises 2026 EPS guidance range Read article
- Medpace (MEDP) Q3 Earnings and Revenues Beat Estimates Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.